Gilead Sciences Inc GILD announced an agreement with Compugen Ltd CGEN to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the COM503 drug candidate.
COM503 is a potential first-in-class, high-affinity antibody that blocks the interaction between IL-18 binding protein and IL-18, releasing natural IL-18 in the tumor microenvironment and inhibiting cancer growth.
Under the terms of the agreement, Compugen will be responsible for the ongoing pre-clinical development and the future Phase 1 study of COM503. After that, Gilead will have the sole right to develop and commercialize COM503.
Gilead will make Compugen an upfront payment of $60 million and $30 million in a near-term milestone payment subject to IND clearance of COM503 expected in 2024.
Compugen will also be eligible to receive up to an additional $758 million in future development, regulatory, and commercial milestone payments, with a total deal value of $848 million.
Compugen will also be eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales.
This transaction with Compugen is expected to reduce Gilead's GAAP and non-GAAP 2023 EPS by approximately $0.03-$0.05.
Concurrently, Compugen also said it will be eligible to receive a milestone payment of $10 million from AstraZeneca Plc AZN when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.
The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects with biliary tract cancer.
Price Action: CGEN shares are up 152.10% at $1.84 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
